Literature DB >> 1651476

Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16.

A Storey1, D Oates, L Banks, L Crawford, T Crook.   

Abstract

A range of specific nuclease resistant phosphorothioate oligodeoxynucleotides (S-oligos) complementary to mRNA of human papillomavirus type 16 (HPV16), were tested for their ability to inhibit cell proliferation and to alter the level of HPV-specific mRNA and proteins in CaSki cells, a human cervical carcinoma cell line containing HPV16 DNA. Only certain of the S-oligos to the viral upstream regulatory region (URR) and the early viral open reading frames (ORF), E6 and E7, were found to display any activity on the cells. These S-oligos were found to exhibit potent anti-proliferative activity at concentrations between 0.25 microM and 20 microM, inhibiting the uptake of [3H]-thymidine into CaSki cells by up to 90% at higher concentrations. The rate of synthesis of E6 and E7 proteins and the steady state level of the E7 protein however remained largely unchanged. E7 protein exhibited a greater decrease in phosphorylation in the presence of only one of the antisense oligos. Other S-oligos including a random sequence, unmodified sequences or O-methylphosphonate modified oligos, had no specific effect on the cells. The results imply that the anti-sense S-oligonucleotides had both specific anti-HPV16 and other non-specific effects on cell proliferation and synthesis of virally encoded proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651476      PMCID: PMC328548          DOI: 10.1093/nar/19.15.4109

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  34 in total

1.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.

Authors:  K Münger; W C Phelps; V Bubb; P M Howley; R Schlegel
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

2.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

3.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.

Authors:  M L Stephenson; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

4.  Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas.

Authors:  L Banks; P Spence; E Androphy; N Hubbert; G Matlashewski; A Murray; L Crawford
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

5.  The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein.

Authors:  D Smotkin; F O Wettstein
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

6.  Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.

Authors:  E Schwarz; U K Freese; L Gissmann; W Mayer; B Roggenbuck; A Stremlau; H zur Hausen
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

7.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Authors:  P C Zamecnik; J Goodchild; Y Taguchi; P S Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

8.  Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.

Authors:  C C Smith; L Aurelian; M P Reddy; P S Miller; P O Ts'o
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

9.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

10.  Comparison of the in vitro transforming activities of human papillomavirus types.

Authors:  A Storey; D Pim; A Murray; K Osborn; L Banks; L Crawford
Journal:  EMBO J       Date:  1988-06       Impact factor: 11.598

View more
  13 in total

1.  Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.

Authors:  R V Giles; D M Tidd
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

Review 2.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

Review 3.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells.

Authors:  R V Giles; C J Ruddell; D G Spiller; J A Green; D M Tidd
Journal:  Nucleic Acids Res       Date:  1995-03-25       Impact factor: 16.971

5.  Activation of human B cells by phosphorothioate oligodeoxynucleotides.

Authors:  H Liang; Y Nishioka; C F Reich; D S Pisetsky; P E Lipsky
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

6.  Loss of muscarinic antinociception by antisense inhibition of M(1) receptors.

Authors:  C Ghelardini; N Galeotti; A Bartolini
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.

Authors:  James D Baleja; Jonathan J Cherry; Zhiguo Liu; Hua Gao; Marc C Nicklaus; Johannes H Voigt; Jason J Chen; Elliot J Androphy
Journal:  Antiviral Res       Date:  2006-04-21       Impact factor: 5.970

8.  A more efficient and specific strategy in the ablation of mRNA in Xenopus laevis using mixtures of antisense oligos.

Authors:  R Morgan; M Edge; A Colman
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

9.  In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts.

Authors:  L M Cowsert; M C Fox; G Zon; C K Mirabelli
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene.

Authors:  E S Hwang; D J Riese; J Settleman; L A Nilson; J Honig; S Flynn; D DiMaio
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.